Skip to Content
Merck
All Photos(2)

Key Documents

View All Documentation

L5918

Sigma-Aldrich

Lomustine

≥98%

Synonym(s):

1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea

Sign Into View Organizational & Contract Pricing
All Photos(2)

About This Item

Empirical Formula (Hill Notation):
C9H16ClN3O2
CAS Number:
13010-47-4
Molecular Weight:
233.70
EC Number:
235-859-2
MDL number:
MFCD00012392
UNSPSC Code:
12352100
PubChem Substance ID:
329817632
NACRES:
NA.25

Quality Level

100

Assay

≥98%

storage temp.

−20°C

SMILES string

ClCCN(N=O)C(=O)NC1CCCCC1

InChI

1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

InChI key

GQYIWUVLTXOXAJ-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Antineoplastic agent with cellular DNA effects. Lomustine induces p53 expression in A2870 cells.

Pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

Signal Word

Danger

Hazard Statements

H301,H350

Precautionary Statements

P201 - P301 + P310 + P330

Hazard Classifications

Acute Tox. 3 Oral - Carc. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tracy T Batchelor et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(26), 3212-3218 (2013-08-14)
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy
C F Saba et al.
Veterinary and comparative oncology, 10(4), 283-291 (2012-01-13)
Treatment of feline vaccine-associated sarcoma (VAS) is challenging, in part due to the high likelihood of tumour recurrence despite aggressive local therapy. Lomustine is potentially an attractive agent to add to the current treatment armamentarium. In this de-escalating phase I/II
Daisuke Hasegawa et al.
The Journal of veterinary medical science, 74(11), 1517-1521 (2012-07-13)
A 9 year-old, neutered, male French Bulldog showing cluster seizures was diagnosed with a glioma in the right piriform cortex by MRI. Hypofractionated radiation therapy (RT) was performed using a linear accelerator. Although the lesion had involuted significantly at 2
Greg Yothers et al.
Journal of the National Cancer Institute, 103(20), 1498-1506 (2011-10-15)
Among patients with resected colon cancer, black patients have worse survival than whites. We investigated whether disparities in survival and related endpoints would persist when patients were treated with identical therapies in controlled clinical trials. We assessed 14,611 patients (1218
Enrico Franceschi et al.
Neuro-oncology, 14(12), 1503-1510 (2012-10-24)
The treatment of patients with recurrent glioblastoma remains a major oncologic problem, with median survival after progression of 7-9 months. To determine the maximum tolerated dose and dose-limiting toxicity (DLT), the combination of dasatinib and cyclonexyl-chloroethyl-nitrosourea (CCNU) was investigated in
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service